PRRT – FDA Approves Lutathera®, What’s Next?
The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community. It has also raised a host of questions including:
- What exactly is
Zebra Tales: Carcinoid NETs Health Storylines Launches New Feature
Carcinoid NETs Health Storylines presents Zebra Tales! This brand new feature enables you to learn and share more about the experiences of others within the neuroendocrine tumor (NET) community.
Our first inspiring story is from Stacie Chevrier –…READ MORE
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors…READ MORE
News about Neuroendocrine Cancer Expert Physicians
Three appointments and a newly established one-year neuroendocrine tumor (NET) fellowship herald an exciting new year for several NET specialists.
Edward M. Wolin, MD, Co-Medical Director of the Carcinoid Cancer Foundation, has…READ MORE
8th Annual Warner Advocacy Award: Call for Nominations
Novartis Oncology and The NET Alliance have announced that nominations are open for the 8th Annual Warner Advocacy Award. This annual award was established by Novartis in 2009 in honor of Monica Warner, who passed away in August 2009, to recognize…READ MORE
NET Community Bicycle Raffle Recipients
In conjunction with Worldwide NET Cancer Awareness Day, November 10, the Carcinoid Cancer Foundation and Advanced Accelerator Applications are very excited to announce recipients of the recent Bicycle Giveaway Raffle.
Stefano Buono, CEO of Advanced…READ MORE
Nutrition for Neuroendocrine Tumors and Carcinoid Syndrome: Find Foods You Love!
Are you wondering what are the best foods to eat if you have carcinoid syndrome? What changes should you make to your diet if you have neuroendocrine tumors? The neuroendocrine tumor (NET) community is invited to attend a national webcast on Wednesday,…READ MORE
Free Kids’ Bicycles for the NET Cancer Community
Do you know a child in the NET cancer community – a child diagnosed with NET cancer or a child living in a family touched by NET disease – who would like to win a bicycle? The Carcinoid Cancer Foundation and Advanced Accelerator Applications are partnering…READ MORE
Carcinoid Syndrome Web Series Continues with Presentation by Michael A. Morse, MD
The neuroendocrine tumor (NET) community is invited to attend a live national webcast by Michael A. Morse, MD (pictured below) on “Testing for Neuroendocrine Tumors and Carcinoid Syndrome” on Wednesday, September 13 at 7:00 pm EST, …READ MORE
October Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community
Join carcinoid and neuroendocrine tumor patients in New York City on Sunday, October 15, 2017 for a unique opportunity to have lunch with three medical experts. Share your experiences with others who have similar concerns and hear from physicians on …READ MORE